IMNX: Immunex Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNX: Immunex Corporation

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

From: Dave Gore	1/8/2001 11:42:12 AM
	Read Replies (1) of 6

IMNX is a superior biotech stock. It is weak lately because the Biotech Index is down, but this is temporary, IMHO. Last time this hit the 20's it bounced up quite quickly and by over 100%. While it may happen slower this time, I think it is a very good buy here with Embrel growth strong and new drugs on the not-to-distant horizon. Once they are able to produce more Embrel and new drugs hit the market earnings should accelerate dramatically. Earnings expected out on Jan. 24th at 8 per share versus 3 cents. GOLDMAN, BEAR STEARNS, ROBBIE STEPHENS LIKE IMNX 15-Dec-00 Immunex Corp (IMNX) 43 13/16 -5/8: Goldman Sachs initiates coverage with a MKT OUTPERFORM; with a broad commercial presence, strong pipeline, and deep capital base, IMNX is well positioned for solid long-term growth; despite near-term capacity constraints for Enbrel, firm believes that the long-term opportunity for sales and label expansion is significant. ** 04-Dec-00 12:00 -- 13:00 ET Immunex Corp (IMNX) 36 3/8 -1 1/4 : Bear Stearns reiterates BUY after company announced a collaboration with Cambridge Antibody Technology to develop novel human monoclonal antibodies; under the deal IMNX will receive access to CAT's proprietary antibody phage display technology and eight potential antibody candidates in exchange for an undisclosed fee; firm is positive on the deal and says stock is attractively valued at current levels. Note firm's comments on IMNX from Friday's Intraday note. 29-Nov-00 14:00 -- 15:00 ET Immunex Corp (IMNX) 38 1/2 +31/32: Bear Stearns reiterates BUY following companies announcement that they will collaborate with Abgenix to discover, develop and commercialize fully human monoclonal antibody therapies for various cancers; sees partnership as strengthening IMNX's position in oncology. 19-Oct-00 11:00 -- 12:00 ET Immunex Corp (IMNX) 42 1/2 -3 11/16: Robertson Stephens reiterates BUY. Net-net firm believes quarter was excellent; Enbrel sales for the quarter were $172.1 mln beating firm's estimate of $170.0 mln; company continues to grow core business, Enbrel and had bottom line growth of 50% over a year ago; expects Enbrel sales to drive shareholder value. **

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext